MedTrace Logo

Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

NCT00514020 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2012-11-01

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving fluorouracil together with oxaliplatin and leucovorin works in treating patients with metastatic stomach cancer or gastroesophageal junction cancer.

Conditions

Interventions

DRUG

fluorouracil

Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.

DRUG

leucovorin calcium

through a vein over 2 hours on days 1 and 15.

DRUG

oxaliplatin

500 ml D5W through a vein over 2 hours on days 1 and 15.

GENETIC

gene expression analysis

Blood collection

GENETIC

polymorphism analysis

Blood collection

GENETIC

protein expression analysis

Blood collection

OTHER

pharmacological study

Blood collection

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Laura W. Goff, MD · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-01-31
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514020 on ClinicalTrials.gov